ZBED6-driven nucleotide metabolic reprogramming improves sensitivity to anti-PD1 therapy in NK/T cell lymphoma.
Identifying a genetic resistance marker in a rare aggressive lymphoma enables potential companion diagnostic and therapy pairing for a disease with limited treatment options.
Using a rigorous 280-day, 5-round anti-PD1 resistance induction protocol with humanized PBMC immune reconstitution in vivo, the authors identified ZBED6 as a key transcriptional repressor whose downregulation enables NKTL cells to scavenge thymidine from the TME via SLC29A1, sustaining proliferation while establishing immunosuppression. Clinical NKTL sample validation of ZBED6 as a resistance biomarker positions this as a potential companion diagnostic and combination therapy target for a highly aggressive rare lymphoma with limited treatment options.
What the study was
- Study design
- mechanistic_preclinical
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Drug Resist Updat
Why it surfaced
NKTL has very high unmet need with limited effective therapies; multi-omic mechanistic approach (transcriptomics, proteomics, metabolomics) with clinical sample validation; novel nucleotide metabolic mechanism for PD-1 resistance; Drug Resistance Updates is specialty journal for this topic.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.